UNSPSC 51272116: Tolycaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C15H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23212OEY8I, chemically known as 2-(2-(diethylamino)acetamido)-m-toluic acid methyl ester monohydrochloride, but more generally known as tolycaine hydrochloride, which bears US NIH Compound Identifier 197869. European Medicines Agency schedules tolycaine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11183MIG.

Most nations, for tariff purposes, schedule tolycaine hydrochloride under HS 29242995. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C(=O)OC)C.CL.

UNSPSC 51272116 Tolycaine hydrochloride is a Commodity code nominally focused on a local anesthetic pharmaceutical agent, but recent state and local solicitation activity shows minimal alignment with this specific product. Instead, the code appears tagged to broader pharmaceutical procurement covering naloxone, generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments purchasing under this code are acquiring pharmaceutical inventory for public health initiatives, community health facilities, and employee health plans through competitive bidding, cooperative purchasing arrangements, and market-research phases. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). Work types range from direct product procurement with quarterly delivery schedules to exploratory requests for vendor capabilities around direct-to-manufacturer contracting models and value-based pharmaceutical agreements.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with bids due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with a response deadline of April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The MMCAP solicitation requires vendor compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, with pricing weighted at 75 percent and administrative fee compliance at 5 percent.